Nombre del producto:Dimethyl acetone-1,3-dicarboxylate

IUPAC Name:1,5-dimethyl 3-oxopentanedioate

CAS:1830-54-2
Fórmula molecular:C7H10O5
Pureza:95%+
Número de catálogo:CM250624
Peso molecular:174.15

Unidad de embalaje Stock disponible Precio($) Cantidad
CM250624-500g in stock Ÿȋ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1830-54-2
Fórmula molecular:C7H10O5
Punto de fusión:-
Código de sonrisas:C(C(CC(OC)=O)=O)C(OC)=O
Densidad:
Número de catálogo:CM250624
Peso molecular:174.15
Punto de ebullición:262.1°C at 760 mmHg
Nº Mdl:MFCD00008462
Almacenamiento:Store at 2-8°C.

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Setanaxib
Genkyotex SA’s Setanaxib (GKT 831) is a small molecule NOX inhibitor currently in Phase III clinical trials and a potential treatment solution for Primary Biliary Cholangitis (PBC). PBC is a chronic and progressive condition characterized by the inflammation and subsequent destruction of the small bile ducts within the liver. Setanaxib is a novel selective inhibitor of NADPH oxidase (NOX) 1 and 4 isoforms, enabling the downregulation of multiple fibrogenic and inflammatory pathways to prevent progression of liver fibrosis. The mechanism of action of setanaxib involves both anti-fibrotic and anti-inflammatory effects.